Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for diseases of the gastrointestinal (GI) tract. The company operates within the biotechnology and pharmaceuticals industry, with an emphasis on conditions involving inflammation, tissue injury, and compromised mucosal integrity. Palisade Bio’s core strategy is to advance drug candidates that leverage endogenous protective pathways to restore gut barrier function.
The company’s primary value driver is its lead clinical asset, LB1148, an orally administered formulation of protease inhibitors designed to reduce inflammation and tissue damage in the GI tract. Palisade Bio targets hospital-based and specialty care markets, particularly patients undergoing major abdominal or GI-related surgeries. The company positions itself around a differentiated mechanistic approach focused on preventing post-surgical complications rather than treating them after onset. Palisade Bio was founded in 2019 and became a public company through a reverse merger and rebranding transaction, evolving from an earlier-stage biotech platform into a focused GI therapeutics developer.
Business Operations
Palisade Bio operates as a single-segment enterprise centered on drug research and clinical development, with no approved commercial products as of the latest public disclosures. The company’s operations are primarily directed toward advancing LB1148 through clinical trials, regulatory engagement, and manufacturing preparation. Revenue generation is currently non-operational, with funding derived from equity offerings and other financing activities rather than product sales.
Operationally, Palisade Bio relies on a combination of internal management and third-party contract research organizations (CROs) and manufacturers to conduct preclinical studies, clinical trials, and drug production. The company does not report meaningful international commercial operations, though certain clinical and manufacturing activities may involve non-U.S. vendors. No material joint ventures or revenue-generating subsidiaries have been conclusively disclosed in public filings.
Strategic Position & Investments
The company’s strategic direction is centered on advancing LB1148 into later-stage clinical development for indications such as post-operative GI recovery and inflammatory bowel-related complications. Growth initiatives focus on expanding the clinical indication set of its lead asset and optimizing trial design to demonstrate reductions in hospital stay, complications, and healthcare costs.
Palisade Bio has not disclosed significant acquisitions or a diversified investment portfolio. Its capital allocation strategy is primarily directed toward internal R&D investment rather than external acquisitions. The company continues to evaluate additional GI-related indications and adjacent inflammatory conditions, though public disclosures beyond its lead program are limited. Data inconclusive based on available public sources regarding near-term expansion into non-GI therapeutic areas.
Geographic Footprint
Palisade Bio is headquartered in the United States, with its principal executive offices located in Massachusetts. The company’s operational footprint is predominantly U.S.-based, reflecting its focus on U.S. regulatory pathways and clinical trial infrastructure.
While Palisade Bio does not maintain a broad global commercial presence, it may engage with international clinical sites or manufacturing partners as part of its development programs. There is no verified evidence of material revenue, subsidiaries, or standalone operations in Europe, Asia-Pacific, or other regions as of the most recent public disclosures.
Leadership & Governance
Palisade Bio is led by an executive team with experience in biotechnology development, clinical strategy, and public company governance. Leadership emphasizes disciplined capital management, targeted clinical development, and regulatory alignment as core elements of the company’s operating philosophy.
Key executives include:
- J.D. Finley – Chief Executive Officer
- Thomas B. Shea – Chief Financial Officer
- Mitesh J. Vora – Chief Operating Officer
- Michael R. Berridge, Ph.D. – Chief Development Officer
The board of directors includes members with backgrounds in pharmaceuticals, finance, and healthcare investing, supporting oversight of strategy, risk management, and shareholder alignment.